产品
编 号：F611588
分子式：C17H11BrClNO3S2
分子量：456.76
分子式：C17H11BrClNO3S2
分子量：456.76
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 685119-25-9
产品详情
生物活性：
BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation.
体内研究：
BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats.Animal Model:Male SD rats weighing 80?g are induced by ACLT
Dosage:0.015, 0.15, 1.5 mg/kg
Administration:Intra-articular injection; twice a week for 4 and 8 weeks
Result:Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.
体外研究：
BNTA (0.01-10?μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes.BNTA (0.1 μM; 2 d) increases SOX9 protein markedly.BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes.BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells.BNTA (0.01-10?μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes.BNTA (0.01-10?μM; 6 h) increases Col2a1, Acan, Prg4, and Sox9 mRNA levels, with maximum effects around 0.1?μM in IL1β-induced rat OA chondrocytes.BNTA (0.01-1?μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants.
BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation.
体内研究：
BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats.Animal Model:Male SD rats weighing 80?g are induced by ACLT
Dosage:0.015, 0.15, 1.5 mg/kg
Administration:Intra-articular injection; twice a week for 4 and 8 weeks
Result:Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.
体外研究：
BNTA (0.01-10?μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes.BNTA (0.1 μM; 2 d) increases SOX9 protein markedly.BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes.BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells.BNTA (0.01-10?μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes.BNTA (0.01-10?μM; 6 h) increases Col2a1, Acan, Prg4, and Sox9 mRNA levels, with maximum effects around 0.1?μM in IL1β-induced rat OA chondrocytes.BNTA (0.01-1?μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备